Ledger · 2026-08-28 · Biotechnology / Cryobiology

Recombinant Ice-Binding Proteins (IBPs) via Methylotrophic Yeast Fermentation

Rejected

This concept did not clear the framework. The reasoning is published in full below.

Why it failed

Assessment

The concept fails like-for-like form factor by comparing an unformulated active protein additive against a bulk solvent CPA (DMSO) or an untreated dough control. Furthermore, IBPs only partially replace cryoprotectant functions (preventing recrystallization rather than colligative ice suppression) and the report lacks a quantified head-to-head numerical viability percentage against DMSO.

Claimed advantage

Near-total inhibition of ice recrystallization and >2x dough gas retention over untreated control, but no quantified head-to-head numerical percentage vs DMSO

Named comparator: DMSO / Glycerol CPAs

A rejection is not a claim that the science is wrong. It means the venture case did not survive: the comparator was not what the buyer actually buys, the comparison was not like-for-like, the advantage fell short of a step change, or the capital and time to first revenue were prohibitive.

Assessed 2026-08-28 against seven gates plus the voiding sub-tests. How the method works · Browse all concepts